At 250 sites world wide the Eurolyser smart 546 was selected to perform patient near testing for an open-label  multicentre  randomised  3-arm study It is to investigate the comparative efficacy and safety of intravenous ferric carboxymaltose versus oral iron for the treatment of iron deficiency anaemia in subjects with non-dialysis-dependent chronic kidney disease